Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Jun 2011

Bekaii-Saab Tanios, Phelps Mitch A, Li Xiaobai, Saji Motoyasu, Goff Laura, Kauh John Sae Wook, O'Neil Bert H, Balsom Stephanie, Balint Catherine, Liersemann Ryan, Vasko Vasily V, Bloomston Mark, Marsh William, Doyle L Austin, Ellison Gilian, Grever Michael, Ringel Matthew D, Villalona-Calero Miguel A

Abstract excerpt

PURPOSE: Biliary cancers (BCs) carry a poor prognosis, but targeting the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) pathway is of significance. Selumetinib is an inhibitor of MEK1/2, so this trial was designed to determine the safety and efficacy of selumetinib in BC. PATIENTS AND METHODS: This was a multi-institutional phase II study of selumetinib at 100 mg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Biliary Tract Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins c-akt

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 21519026
DOI: 10.1200/JCO.2010.33.9473
PMCID: PMC3107751

Genes

BRAF
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.PMID 21519026Read ↗

Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors.Semantic proximity Read ↗

HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.Semantic proximity Read ↗

Antitumor Activity in <i>RAS</i> -Driven Tumors by Blocking AKT and MEKSemantic proximity Read ↗

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Semantic proximity Read ↗

Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.Semantic proximity Read ↗

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.Semantic proximity Read ↗

Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case SeriesSemantic proximity Read ↗

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.Semantic proximity Read ↗

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Semantic proximity Read ↗

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.Semantic proximity Read ↗

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.